+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Herpes Treatment Market 2020-2024 - Product Image

Global Herpes Treatment Market 2020-2024

  • ID: 5135387
  • Report
  • July 2020
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Cipla Inc.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck & Co. Inc.
  • MORE
Global Herpes Treatment Market 2020-2024

The herpes treatment market is poised to grow by $ 677.02 mn during 2020-2024 progressing at a CAGR of 4% during the forecast period. The report on herpes treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of herpes infection, large patient pool and rising prevalence rate of shingles in the older population. In addition, increasing prevalence of herpes infection is anticipated to boost the growth of the market as well.

The herpes treatment market analysis includes type segment and geographic landscapes.

The herpes treatment market is segmented as below:

By Type
  • Herpes zoster
  • Herpes simplex
By Geographic Landscapes
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the emergence of novel therapies as one of the prime reasons driving the herpes treatment market growth during the next few years. Also, increasing focus on vaccine development and increasing focus on drug development for pre-adolescent patients will lead to sizable demand in the market.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The herpes treatment market covers the following areas:
  • Herpes treatment market sizing
  • Herpes treatment market forecast
  • Herpes treatment market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading herpes treatment market vendors that include Bausch Health Companies Inc., Cipla Inc., Eli Lilly and Co., Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, and Teva Pharmaceutical Industries Ltd.. Also, the herpes treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cipla Inc.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck & Co. Inc.
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Type
  • Market segments
  • Comparison by Type
  • Herpes zoster - Market size and forecast 2019-2024
  • Herpes simplex - Market size and forecast 2019-2024
  • Market opportunity by Type
Customer Landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Competitive Scenario
  • Vendor landscape
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ million)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Type - Market share 2019-2024 (%)
22: Comparison by Type
23: Herpes zoster - Market size and forecast 2019-2024 ($ million)
24: Herpes zoster - Year-over-year growth 2019-2024 (%)
25: Herpes simplex - Market size and forecast 2019-2024 ($ million)
26: Herpes simplex - Year-over-year growth 2019-2024 (%)
27: Market opportunity by Type
28: Customer Landscape
29: Market share by geography 2019-2024 (%)
30: Geographic comparison
31: North America - Market size and forecast 2019-2024 ($ million)
32: North America - Year-over-year growth 2019-2024 (%)
33: Europe - Market size and forecast 2019-2024 ($ million)
34: Europe - Year-over-year growth 2019-2024 (%)
35: Asia - Market size and forecast 2019-2024 ($ million)
36: Asia - Year-over-year growth 2019-2024 (%)
37: ROW - Market size and forecast 2019-2024 ($ million)
38: ROW - Year-over-year growth 2019-2024 (%)
39: Key leading countries
40: Market opportunity by geography ($ million)
41: Impact of drivers and challenges
42: Vendor landscape
43: Landscape disruption
44: Industry risks
45: Vendors covered
46: Market positioning of vendors
47: Bausch Health Companies Inc. - Overview
48: Bausch Health Companies Inc. - Business segments
49: Bausch Health Companies Inc. - Key offerings
50: Bausch Health Companies Inc. - Key customers
51: Bausch Health Companies Inc. - Segment focus
52: Cipla Inc. - Overview
53: Cipla Inc. - Business segments
54: Cipla Inc. - Key offerings
55: Cipla Inc. - Key customers
56: Cipla Inc. - Segment focus
57: Eli Lilly and Co. - Overview
58: Eli Lilly and Co. - Business segments
59: Eli Lilly and Co. - Key offerings
60: Eli Lilly and Co. - Key customers
61: Eli Lilly and Co. - Segment focus
62: Gilead Sciences Inc. - Overview
63: Gilead Sciences Inc. - Product and service
64: Gilead Sciences Inc. - Key offerings
65: Gilead Sciences Inc. - Key customers
66: Gilead Sciences Inc. - Segment focus
67: GlaxoSmithKline Plc - Overview
68: GlaxoSmithKline Plc - Business segments
69: GlaxoSmithKline Plc - Key offerings
70: GlaxoSmithKline Plc - Key customers
71: GlaxoSmithKline Plc - Segment focus
72: Maruho Co. Ltd. - Overview
73: Maruho Co. Ltd. - Product and service
74: Maruho Co. Ltd. - Key offerings
75: Maruho Co. Ltd. - Key customers
76: Maruho Co. Ltd. - Segment focus
77: Merck & Co. Inc. - Overview
78: Merck & Co. Inc. - Business segments
79: Merck & Co. Inc. - Key offerings
80: Merck & Co. Inc. - Key customers
81: Merck & Co. Inc. - Segment focus
82: Mylan NV - Overview
83: Mylan NV - Business segments
84: Mylan NV - Key offerings
85: Mylan NV - Key customers
86: Mylan NV - Segment focus
87: Novartis AG - Overview
88: Novartis AG - Business segments
89: Novartis AG - Key offerings
90: Novartis AG - Key customers
91: Novartis AG - Segment focus
92: Teva Pharmaceutical Industries Ltd. - Overview
93: Teva Pharmaceutical Industries Ltd. - Business segments
94: Teva Pharmaceutical Industries Ltd. - Key offerings
95: Teva Pharmaceutical Industries Ltd. - Key customers
96: Teva Pharmaceutical Industries Ltd. - Segment focus
97: Currency conversion rates for US$
98: Research Methodology
99: Validation techniques employed for market sizing
100: Information sources
101: List of abbreviations
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Cipla Inc.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck & Co. Inc.
  • MORE
The publisher recognizes the following companies as the key players in the global herpes treatment market: Bausch Health Companies Inc., Cipla Inc., Eli Lilly and Co., Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, and Teva Pharmaceutical Industries Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is emergence of novel therapies."

According to the report, one of the major drivers for this market is the increasing prevalence of herpes infection.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll